We use the value-per-statistical-life method to estimate the global value of a prospective Strep-A vaccine. Using a novel Strep-A epidemiological model, we estimate the expected number of cases averted, deaths averted and DALYs averted globally if a Strep-A vaccine were available, accounting for a phased adoption of the vaccine across countries. The value-per-statistical-life method captures the intrinsic and instrumental value of living longer and in better health thanks to vaccination. There are ethical objections to the use of country-specific value-per-statistical-life measures because they tend to undervalue health benefits accruing to less developed countries. We address these concerns in two ways: i) using a global estimate of the value-per-statistical-life to be applied to all countries; ii) adjusting (with appropriate distributional weights) differences in value-per-statistical-life due to differences in the value of money across countries. We compare the estimates derived from the value-per-statistical-method with those derived from the cost-of-illness approach. Sensitivity analyses are performed to account for different characteristics of the prospective vaccine, and different measures of value-per-statistical-life.